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Idiopathic pulmonary haemosiderosis. 
Epidemiology, pathogenic aspects and diagnosis 
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Department of Pulmonary Medicine, Nastved Hospital, Nczstved, Denmark 
Idiopathic pulmonary haemosiderosis (IPH) is a rare clinical entity characterized by recurrent episodes of diffuse 
alveolar haemorrhage, often presenting with haemoptysis. Many patients have iron deficiency anaemia due to 
deposition of haemosiderin iron’m the alveoli, and eventually develop moderate pulmonary fibrosis. Typically, 
intensive search for an aetiology ends up negative. There is no evidence of pulmonary vasculitis or capillaritis. The 
aetiology is obscure, but may be an immunological or toxic mechanism causing a defect in the basement membrane 
of the pulmonary capillary. IPH affects both children and adults. During an acute episode, a chest X-ray 
demonstrates bilateral, alveolar infiltrates. Sputum examination discloses haemosiderin-laden alveolar macrophages. 
Diagnosis is established by lung biopsy (fiber-optic or thoracoscopic), showing large numbers of haemosiderin-laden 
macrophages in the alveoli and without evidence of capillaritis or deposition of immunoglobulins. Corticosteroids 
and/or immunosuppressive drugs may be effective during an acute bleeding episode, and may in some patients 
improve symptoms and prognosis on the long-term, but the response to treatment displays great interindividual 
variation. 
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Introduction 
Diffuse alveolar haemorrhage, which is caused by a range 
of different disorders, is clinically characterized by dysp- 
noea and haemoptysis, and associated with bilateral, diffuse 
alveolar infiltrates on chest X-ray as well as anaemia. 
Diseases associated with diffuse alveolar haemorrhage are 
shown in Table 1. Recurrent acute or chronic disorders with 
intrapulmonary bleeding may eventually produce pulmon- 
ary haemosiderosis. In some patients, intensive search for 
a specific aetiology ends up negative, and such cases are 
at the present classified as having idiopathic pulmonary 
haemosiderosis (IPH). 
IPH was initially described by Virchow in 1864 (1). In 
1931 Ceelen (2) published a description of the disease 
including the autopsy findings in two children having large 
amounts of haemosiderin deposited in the lungs. The 
disease was subsequently defined as a clinical entity com- 
prising the triade of haemoptysis, pulmonary infiltrates, 
and anaemia, in which the aetiology was unknown (3). A 
biopsy specimen from the lung should demonstrate haemo- 
siderosis without evidence of vasculitis, capillaritis, inflam- 
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mation, granulomas or deposition of immunoglobulins in 
any specific pattern (4). 
Epidemiology 
The true incidence and prevalence of IPH is unknown. 
Approximately 2.50 patients have been reported in the 
literature. In a Swedish study the estimated incidence 
among children was 0.21 per 100 000 persons per year (5). 
In children, the disease often begins before the age of 
10 years (3). In adults, most cases are recognized before 
30 years of age. In childhood, IPH occurs with equal 
frequency in the two genders, whereas in adulthood the 
disease appears to be more frequent in men (6,7). Familial 
clustering has been reported in two brothers (8), in mono- 
zygotic twins (9) and in a mother and her son (10). 
Matsaniotis et al. (11) described clustering of cases with 
IPH in a small isolated society with a high coefficient of 
consanguinity. These findings suggest that genetics may 
play a role in the development of IPH, and that environ- 
mental factors could precipitate the disease in genetically 
predisposed individuals (12). 
Aetiology 
The aetiology of IPH is unknown. Some children with IPH 
have plasma antibodies (precipitins and IgE) against cow’s 
milk, giving birth to the hypothesis that the disease might 
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TABLE 1. Disorders associated with diffuse alveolar 
haemorrhage 
Disorders without pulmonary capillaritis 
Idiopathic pulmonary haemosiderosis 
Mitral stenosis 
Primary pulmonary hypertension 
Pulmonary vascular malformation 
Pulmonary lymphangioleiomyomatosis 
Systemic disorders with pulmonary capillaritis 
Goodpasture’s syndrome 
Idiopathic pulmonary renal syndrome 
IgA nephropathy 
Systemic lupus erythematosus 
Other collagen vascular diseases 
Wegener’s granulomatosis 
Behcet’s syndrome 
Microscopic polyangiitis 
Antiphospholipid antibody syndrome 
Henoch-Schonlein purpura 
Drug induced capillaritis (penicillamine, 
diphenylhydantoin) 
Cryoglobulinaemia 
Pulmonary capillaritis without systemic disorder 
Isolated pauciimmune pulmonary capillaritis 
be caused by an allergic reaction to milk (13,14). Other 
authors have failed to reproduce these findings, which may 
be explained by an accidental coexistence of the two 
diseases (15,16). 
Apparently, there is a defect in the alveolar capillaries 
either in the alveolar basement membrane or in the 
endothelial cell (17-20). Circulating plasma immune com- 
plexes have been demonstrated in a few patients (16). 
However, immunohistochemical examination of lung 
tissue has not produced evidence of an immunological 
pathogenesis (17,18,21,22). 
The coexistence of coeliac disease and IPH, which has 
been reported in some patients, is in favour of an immuno- 
logical pathogenesis (23328). The literature reports at least 
10 cases with coexistent coeliac disease and IPH. In some of 
these patients, a gluten-free diet induced remission of the 
pulmonary symptoms (23,25,26). However, the possible 
pathogenic link between coeliac disease and IPH is still 
unclarified. 
Pathology 
At macroscopic examination, in advanced cases of IPH, the 
lungs show a striking brown appearance due to siderosis 
with varying degree of pulmonary fibrosis. Examination by 
light microscopy of a lung biopsy specimen demonstrates as 
a characteristic, but entirely unspecific finding, that the 
alveoli contain numerous haemosiderin-laden macrophages 
(Plate 1). In association with recent pulmonary bleeding, 
erythrocytes can be found in the alveoli as well. 
The alveolar capillaries are often dilated, tortuous and 
may protude into the alveolar lumen (15). A capillary lesion 
PLATE 1. Fiber-optic, transbronchial forceps lung biopsy 
specimen from the right middle lobe in a 55-year-old 
woman with idiopathic pulmonary haemosiderosis (32). 
Slight thickening of the alveolar walls, proliferation of 
Type II pneumocytes, and alveoli filled with haemosiderin- 
laden macrophages. Combined staining for iron (Perls’ 
Prussian blue) and cytokeratin no. 7 (immunoperoxidase). 
Magnification x 400 (Courtesy by Chief Physician Per 
Pratorius Clausen, Department of Pathology, Nzstved 
Hospital, DK-4700 NLestved, Denmark). 
and leak is a prerequisite for diffuse alveolar haemorrhage, 
but in IPH there is no histological or immunohistochemical 
evidence of a pulmonary capillaritis (29,30). The criteria for 
diagnosis of pulmonary capillaritis include: patchy infiltra- 
tion of alveolar septa by neutrophils, accompanied by 
nuclear dust; local expansion, disruption and necrosis of 
alveolar septa, which may be replaced by a neutrophil 
infiltrate; proteinaceous exudate with nuclear debris within 
alveolar spaces; acute and chronic alveolar haemorrhage 
containing fragmented neutrophils (3 1). 
The alveolar walls are thickened, and the Type II pneu- 
mocytes appear enlarged and sometimes hyperplastic. 
Localized interstitial fibrosis with formation of collagen is a 
prominent feature in long-standing disease (17-19,22.32). 
Examination by electron microscopy demonstrates 
swollen alveolar endothelial cells containing vacuoles (17). 
The basement membrane of the alveolear capillaries may 
present focal thickening (17,18), and some authors have 
described localized discontinuities with rupture of the mem- 
brane (l&20). Other studies have failed to reproduce 
this finding (17,22). Electron-dense material close to the 
basement membrane suggesting deposition of immune 
complexes has not been found (17). 
Symptoms, Clinical and Paraclinical 
Features 
In children, IPH often begins before 10 years of age with 
recurrent episodes of dyspnoea and cough. In the begin- 
ning, the cough is predominantly irritative. Later in the 
course of the disease. haemoptyses occur, occasionally 
with overt bleeding from the lower respiratory tract. The 
children fail to thrive and develop moderate to severe 
anaemia, which may present with the features of an iron 
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deficiency anaemia (3,6,33). In fact, iron deficiency anaemia 
may be the only clinical finding. As the blood-stained 
sputum is often swallowed, the children may present with a 
positive test for blood in the faeces (33). Approximately 
20% have enlargement of the liver and/or spleen and slight 
to moderate lymphadenopathy (3,6). 
In adults, the most frequent symptoms comprise exer- 
tional dyspnoea and fatigue due to intrapulmonary bleed- 
ing and iron deficiency anaemia (32). Nearly all patients 
have haemoptyses, which may range from occasionally 
blood stained sputum to regular, daily haemoptyses and 
frank bleeding (6,32). Sudden death due to massive intra- 
pulmonary bleeding has been reported in some cases (34). 
Following an acute bleeding episode, a high number of 
reticulocytes may be present in the blood (32). Absorption 
of haemoglobin from the lungs induces a rise in plasma 
bilirubin and in the urinary excretion of urobilinogen. 
Estimation of the mean red cell survival time using 5’Cr 
labelled autologous erythrocytes shows a reduced survival 
time due to deposition of red blood cells in the lungs (32). 
Therefore, in many aspects, IPH can mimic a haemolytic 
anaemia. The majority of the patients with longstanding 
disease will, due to the blood losses in the lungs, develop 
iron deficiency anaemia, with red cell microcytosis and a 
transferrin saturation below 15%. The anaemia responds to 
treatment with iron. A bone marrow biopsy typically shows 
a hyperplastic erythropoiesis, often without stainable 
haemosiderin iron (6,32). 
Serum ferritin levels, which in healthy subjects reflect 
mobilizable body iron stores (35) may be misleading in 
IPH, because they apparently also reflect the non- 
mobilizable haemosiderin iron located in the lungs. Iron 
deficient erythropoiesis is usually associated with serum 
ferritin levels below 15 ug l- ’ (36). Recently, two cases 
with IPH having normal serum ferritin levels despite iron 
deficiency anaemia, have been reported (32). 
Following an acute episode with pulmonary bleeding, 
chest X-ray demonstrates unilateral or bilateral, poorly de- 
fined opacities with an alveolar distribution pattern, which 
may show partial or complete regression in the symptom- 
free phase (6,32,37). High resolution computed tomography 
(CT)-scan of the chest shortly after bleeding shows diffuse 
alveolar opacifications, most prominent in the lower 
lobes (32). Pulmonary perfusion-ventilation scintigraphy is 
normal without evidence of pulmonary emboli (32). 
Indirect evidence for ongoing intrapulmonary bleeding 
can be obtained by pulmonary radioscintigraphy, per- 
formed with an intravenous injection of autologous 
erythrocytes labelled with 99mTc or “Cr and subsequent 
recording of the radioactivity in the lungs with a gamma 
camera (38,39). Furthermore, during an acute bleeding 
episode, the haemoglobin present in the red blood cells in 
the alveoli binds CO, thus producing an inappropriately 
high &CO value (40). When the haemoglobin has been 
degraded, the D,CO declines to levels which reflect the 
transport of CO across the alveolar membrane. 
Long standing disease is followed by the development 
of secondary pulmonary fibrosis (6). Accordingly, lung 
function tests show an impaired function with a restrictive 
pattern, i.e. a low FEV, and VC, a normal or increased 
FEV,IVC ratio, and a low TLC together with a low &CO 
(32,41). 
Iron metabolism 
The monocyte-macrophage system displays great hetero- 
geneity between different organs. The macrophages in the 
liver, spleen and bone marrow are specifically designed to 
degrade senescent erythrocytes and reprocess the haemo- 
globin iron (42,43). Cultured macrophages derived from 
blood monocytes phagocytize more than six times as many 
denaturated red blood cells as cultured alveolar macro- 
phages (44). Furthermore, cultured blood macrophages 
exhibit markedly greater capacity to metabolize haemo- 
globin iron than cultured alveolar macrophages (44). 
In viva, alveolar macrophages are apparently unable to 
metabolize haemoglobin iron, since alveolar haemorrhage 
results in accumulation of ample amounts of haemosiderin 
iron in the alveolar macrophages. This haemosiderin iron is 
trapped, and therefore not available for the synthesis of 
haemoglobin (44) but nevertheless induces an increase in 
the serum ferritin level (32). Recurrent haemorrhage results 
in continuous iron accumulation, and the presence of free 
iron in the tissues, which eventually may produce pulmon- 
ary fibrosis (44,45). Thus IPH is characterized by the 
paradox of an iron deficiency anaemia, often with absent 
bone marrow iron stores, despite the presence of ample 
amounts of haemosiderin iron in the alveoli. 
It is recognized that moderate to severe parenchymal iron 
overload in the liver, pancreas and heart is toxic to the cells, 
causes cell death, stimulates fibrogenesis and the formation 
of collagen connective tissue (46). The proposed mechan- 
isms include lipid peroxidation with damage to intracellular 
organelles, and activation of lipocytes, which produce 
increased amounts of collagen (46). The toxic properties of 
iron have been studied most extensively in the liver, in 
which the outcome may be hepatic fibrosis or cirrhosis, as 
encountered in patients with hereditary haemochromatosis 
(46,47). 
Diagnosis 
There are no features, which are pathognomonic for IPH, 
and the diagnosis therefore relies on the exclusion of 
other disorders in which diffuse alveolar haemorrhage is a 
cardinal sign (Table 1). 
The diagnosis is made by combining particular clinical 
findings (haemoptysis, cough and dyspnoea) with particular 
paraclinical findings (chest X-ray opacities, iron deficiency 
anaemia) together with lung biopsy specimens showing 
alveoli filled with haemosiderin-laden macrophages. Lung 
biopsy specimens should initially be obtained by fiber-optic 
bronchoscopy with transbronchial forceps lung biopsy, 
which is a minor invasive procedure. Multiple (four to 10) 
biopsy specimens should be obtained from different lobes 
and segments in one of the affected lungs. However, if a 
definite diagnosis cannot be made on these relatively small 
biopsy specimens, larger specimens should be obtained by 
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either thoracoscopic or open lung biopsy. Haemosiderin- 
laden alveolar macrophages are likewise present in bron- 
choalveolar lavage (BAL) fluid and may be found in the 
sputum. They confirm the presence of alveolar haemor- 
rhage but cannot be employed as a specific diagnostic 
criterion for IPH. 
The biopsy specimens should be processed for immuno- 
fluorescence studies and electron microscopy in addition to 
the light microscopic studies. Biopsies should be without 
specific pathological findings, i.e. no granulomas indicating 
mycobacterial infection, sarcoidosis or Wegener’s granulo- 
matosis, no evidence of vasculitis/capillaritis or specific 
deposition of immunoglobulins, and no evidence of other 
infections or pulmonary infarction. 
Patients should have their anaemia classified by appropri- 
ate laboratory tests (serum ferritin, transferrin saturation, 
plasma cobalamine, red cell folate, plasma immuno- 
globulins, plasma electrophoresis, plasma cryoglobulins, 
plasma complement levels, tests for haemolysis and haemo- 
globinopathy ect.) and if indicated a bone marrow biopsy 
and examination for occult bleeding from the gastro- 
intestinal, urinary or genital tract should be performed. 
Screening for coagulation defects as well as autoimmune 
disorders should be part of the routine evaluation. There 
should be no evidence of autoimmune disease, i.e. no 
autoantibodies in plasma, such as antinuclear antibodies 
(ANA), anti-DNA, antineutrophil cytoplasmatic antibodies 
(ANCA), antiglomerular basement membrane (GBM) anti- 
bodies, antiphospholipid antibodies or rheumatoid factors. 
The patients should also be screened for plasma antibodies 
against gliadin and reticulin and have a complete examina- 
tion for allergy, including skin prick test with appropriate 
antigens, blood eosinophils, plasma IgE, and antibodies to 
cow’s milk. Furthermore, there should be no evidence of 
glomerulitis, i.e. normal renal function and urine analysis 
without proteinuria or haematuria. 
High resolution CT scan of the thorax allows a precise 
location and classification of the opacities seen on chest 
X-ray, and is a useful tool in the diagnostic evaluation. 
Pulmonary function tests should include both dynamic and 
static lung volumes as well as D, CO. 
New diagnostic techniques have emerged during the last 
decades, such as minimally invasive biopsy procedures 
(fiber-optic bronchoscopy with transbronchial lung biopsy 
and BAL), and immunohistochemistry with assessment of 
deposition of immunoglobulins and or immune complexes 
in lung and renal tissue specimens. Furthermore, sensitive 
assays for the detection of autoimmune antibodies in 
plasma, e.g. anti-GBM antibodies, ANCA and antiphos- 
pholipid antibodies have become available as a routine. 
These techniques, which allow a more reliable classification 
of cases with diffuse alveolar haemorrhage, were not per- 
formed in earlier series. Older studies may therefore com- 
prise patients not having IPH by the criteria used in this 
review, but some of the other disorders listed in Table 1. In 
the years to come, new diagnostic methods will enable the 
clinician to delineate more specifically patients with IPH, 
and to re-evaluate both the epidemiology and the prog- 
nosis of the disease. Time will show whether IPH can be 
maintained as a separate clinical entity. 
Prognosis 
Due to the lack of large and comparable patient series, and 
inadequate follow-up, the prognosis of IPH is difficult to 
assess. In the studies of Soergel and Sommers (6): the 
average survival from the beginning of symptoms until 
death was 2.5 years with a wide range from days to several 
years, However, the follow-up of many patients was incom- 
plete. The authors summarized the status of 68 patients. 
Twenty patients had died, they had a mean duration of 
disease of 3.3 years; 17 had active disease, and a mean 
duration of disease of 5.5 years; 12 had chronic active 
disease with persisting symptoms consisting of dyspnoea 
and anaemia, and a mean duration of disease of 5.4 years; 
19 appeared healthy without symptoms or signs of disease, 
they had a mean duration of disease of 4.5 years (6). The 
two most frequent causes of death were acute pulmonary 
bleeding and/or chronic pulmonary insufficiency (6,33). 
In the literature review by Bronson (7) of 38 patients with 
IPH, the mean survival time from the initial symptoms to 
death was likewise 2.5 years. Among those patients, who 
were alive at the follow-up, the mean observation period 
was about 1 year (7). 
It appears that the survival time displays wide variation. 
There is a tendency that in children and adolescents the 
disease may take a rapid course and carry a poor prognosis. 
In adults, the course is often prolonged with less pro- 
nounced symptoms and a more favourable prognosis (32). 
Treatment 
As IPH was supposed to have an immunological patho- 
genesis, some patients previously underwent splenectomy, 
which, however, had no effect on the course of the disease. 
Treatment with systemic corticosteroids is commonly 
used, particularly in the acute phase of the disease. The use 
of corticosteroids both in acute disease and as long-term 
treatment is based mainly on empiricism. Due to the 
sporadic occurrence of the disease, no controlled study has 
been performed. Documentation is mostly based on case 
reports (33) or on the series of Soergel and Sommers, which 
comprises 112 patients, in whom clinical data and relevant 
examinations are inadequate in most patients (6). 
Corticosteroids in high doses may reduce the morbidity 
and mortality of an acute episode (6,7,32,33). Long-term 
treatment with systemic corticosteroids in moderately high 
doses, is often without effect in children (6) but may- be 
effective in adults (22,32). Inhaled corticosteroids have 
been tried in cases where systemic treatment proved to 
be ineffective, or was not tolerated (48). Azathioprine, in 
combination with oral corticosteroids, may have a favour- 
able influence on the course of IPH in some patients 
(19,49,50). Treatment with oral corticosteroids is indicated 
in the acute phase of the disease. It is the authors’ experi- 
ence that many adult and elderly patients respond favour- 
ably to oral corticosteroids, i.e. disease activity can be 
controlled and progression of the disease can be delayed or 
even stopped. 
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